Outsourcing, particularly to regions with lower production costs, has become a common practice among pharmaceutical companies. Countries like India and China have emerged as major players in the API manufacturing landscape, offering cost-effective solutions while maintaining compliance with international standards. However, this trend also raises concerns about the quality of APIs and supply chain vulnerabilities, highlighting the need for robust quality assurance mechanisms.
